公司資料
ProKidney 股價、新聞與催化劑
- 股票代碼:
- PROK
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- United States
股票表現
1.61 USD (+13.38%)
收盤價
最後更新: 2026年8月21日
390M USD
市值
股價為何變動
As of Aug 21, 2026, PROK closed up 13.4% at $1.61. No new same-company headline was identified in the current news window.
公司概覽
Regenerative Kidney Medicine
ProKidney develops cell therapies intended to preserve kidney function and delay progression to kidney failure. Its work focuses on patients with advanced chronic kidney disease and type 2 diabetes who face a high risk of dialysis or transplantation.
Rilparencel
Rilparencel, also known as REACT, is a proprietary autologous cell therapy manufactured from a patient's own kidney cells. The product has Regenerative Medicine Advanced Therapy designation and is designed to restore or stabilize kidney function through repeat image-guided injections.
Phase 3 Development
The Phase 3 REGEN-006, or PROACT 1, study evaluates rilparencel against a sham procedure. Its design supports an accelerated-approval analysis based on annualized eGFR slope and a longer confirmatory analysis based on kidney-function decline, dialysis, transplantation, or renal and cardiovascular death.
未來催化劑
- Completion of full enrollment in the Phase 3 REGEN-006 study in the second half of 2026.
- Topline results from the accelerated-approval efficacy analysis of REGEN-006 in the second quarter of 2027.
- Topline results from the confirmatory composite time-to-event analysis of REGEN-006 in the second half of 2029.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。